<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194829</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-01425</org_study_id>
    <secondary_id>NCI-2014-01425</secondary_id>
    <secondary_id>EA2131</secondary_id>
    <secondary_id>EA2131</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT02194829</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase I/II trial studies the side effects and best dose of WEE1&#xD;
      inhibitor MK-1775 when given together with paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation and gemcitabine hydrochloride and how well they work in treating patients with&#xD;
      previously untreated pancreatic cancer that has spread to another place in the body or cannot&#xD;
      be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation and gemcitabine hydrochloride, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. It is not yet known whether paclitaxel&#xD;
      albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride are more effective&#xD;
      with or without WEE1 inhibitor MK-1775 in treating patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the toxicity of combination therapy with nab-paclitaxel (paclitaxel&#xD;
      albumin-stabilized nanoparticle formulation), gemcitabine (gemcitabine hydrochloride) and&#xD;
      AZD1775 (WEE1 inhibitor MK-1775) in patients with treatment-naive metastatic adenocarcinoma&#xD;
      of the pancreas or locally-advanced adenocarcinoma of the pancreas which is not surgically&#xD;
      resectable. (Phase I) II. To determine the dose of AZD1775 to be used in combination with&#xD;
      nab-paclitaxel and gemcitabine chemotherapy in the phase II portion of the trial. (Phase I)&#xD;
      III. To determine the pharmacokinetics of AZD1775 in combination with nab-paclitaxel and&#xD;
      gemcitabine. (Phase I) IV. To evaluate progression-free survival (PFS) associated with&#xD;
      nab-paclitaxel/gemcitabine/placebo or nab-paclitaxel/gemcitabine/AZD1775 in patients with&#xD;
      metastatic adenocarcinoma of the pancreas. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate overall survival (OS) associated with nab-paclitaxel/gemcitabine/placebo or&#xD;
      nab-paclitaxel/gemcitabine/AZD1775 in patients with metastatic adenocarcinoma of the&#xD;
      pancreas. (Phase II) II. To evaluate response rate (complete response [CR] + partial response&#xD;
      [PR]) associated with nab-paclitaxel/gemcitabine/placebo or&#xD;
      nab-paclitaxel/gemcitabine/AZD1775 in patients with metastatic adenocarcinoma of the&#xD;
      pancreas. (Phase II) III. To evaluate disease control rate (CR + PR + stable disease [SD])&#xD;
      associated with nab-paclitaxel/gemcitabine/placebo or nab-paclitaxel/gemcitabine/AZD1775 in&#xD;
      patients with metastatic adenocarcinoma of the pancreas. (Phase II)&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the ability of AZD1775 to inhibit Wee1 and increase deoxyribonucleic acid&#xD;
      (DNA) damage and tumor cell death when combined with nab-paclitaxel/gemcitabine compared to&#xD;
      nab-paclitaxel/gemcitabine/placebo. (Phase II) II. To evaluate if biomarker changes in tumor&#xD;
      tissue associated with Wee1 inhibition may also be present in hair follicles. (Phase II) III.&#xD;
      To evaluate the change in tumor fludeoxyglucose (FDG) uptake (maximum standardized uptake&#xD;
      value [SUVmax]) between baseline FDG-positron emission tomography (PET) and week 4 FDG-PET as&#xD;
      a predictor of response using Response Evaluation Criteria in Solid Tumors (RECIST) as the&#xD;
      reference standard for response. (Phase II) IV. To evaluate the change in tumor FDG uptake&#xD;
      (SUVmax) between baseline FDG-PET and week 4 FDG-PET as a predictor of progression-free&#xD;
      survival. (Phase II) V. To compare the change in tumor FDG uptake (SUVmax) between baseline&#xD;
      FDG-PET and week 4 FDG-PET between the patients from treatment arms C and D. (Phase II) VI.&#xD;
      To evaluate if an early increase in tumor fluorothymidine (FLT) uptake (FLT-flare) is&#xD;
      observed within 24 hours after initiation of treatment with&#xD;
      nab-paclitaxel/gemcitabine/placebo. (Phase II) VII. To evaluate if an early (within 24 hours&#xD;
      [h]) increase in tumor FLT uptake (FLT-flare) is abrogated after initiation of treatment with&#xD;
      nab-paclitaxel/gemcitabine/AZD1775. (Phase II) VIII. To compare the change in tumor FLT&#xD;
      uptake (SUVmax) from baseline to 24 hours after initiation of treatment between the patients&#xD;
      from treatment arms C and D. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose escalation study of WEE1 inhibitor MK-1775 followed by a&#xD;
      randomized phase II study. Patients in phase I are assigned to arm A or B and patients in&#xD;
      phase II are randomized to arm C or D.&#xD;
&#xD;
      ARM A (PHASE I, DOSE LEVEL 1): Patients receive paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation intravenously (IV) over 30 minutes and gemcitabine hydrochloride IV over 30&#xD;
      minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 orally (PO) daily&#xD;
      on days 1, 2, 8, 9, 15, and 16.&#xD;
&#xD;
      ARM B (PHASE I, DOSE LEVEL 2): Patients receive paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.&#xD;
&#xD;
      ARM C (PHASE II, PLACEBO): Patients receive paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily&#xD;
      on days 1, 2, 8, 9, 15, and 16.&#xD;
&#xD;
      ARM D (PHASE II, WEE1 INHIBITOR MK-1775): Patients receive paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.&#xD;
&#xD;
      In all arms, courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <primary_completion_date type="Actual">June 3, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of WEE1 inhibitor MEK-1775, defined as the highest dose level at which &lt; 33% of 6 patients experience a dose-limiting toxicity graded according to Common Terminology Criteria for Adverse Events version 4 (Phase I)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From randomization to documented progression or death without progression, assessed up to 2 years</time_frame>
    <description>PFS by arm will be compared using one-sided log-rank tests. Cox's proportional hazards models will be used to estimate hazard ratios.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to death from any cause, assessed up to 2 years</time_frame>
    <description>OS by arm will be compared using one-sided log-rank tests. Cox's proportional hazards models will be used to estimate hazard ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR + PR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be analyzed using Fisher's exact tests at a one-sided significance level of 0.15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR + PR + SD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be analyzed using Fisher's exact tests at a one-sided significance level of 0.15.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in tumor FDG uptake (SUVmax)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Will be evaluated as a predictor of response using RECIST as the reference standard.</description>
  </other_outcome>
  <other_outcome>
    <measure>Accuracy of change in tumor FDG uptake (SUVmax) between baseline FDG-PET and week 4 FDG-PET as a predictor of progression-free survival</measure>
    <time_frame>Up to week 4</time_frame>
    <description>Time-dependent receiver operator characteristic methodology will be used to assess the ability of SUVmax change to predict PFS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor FDG uptake (SUVmax) between baseline FDG-PET and week 4 FDG-PET</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Will be compared between the patients from treatment arms C and D only as a continuous variable using Wilcoxon test and as binary variable (defined as summed SUVmax change from baseline &lt; -25% versus &gt;= -25%) using Fisher's exact tests.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of an early increase in tumor FLT uptake (FLT-flare) within 24 hours after initiation of treatment</measure>
    <time_frame>Up to 24 hours after initiation of treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of abrogation of early increase in tumor FLT uptake after initiation of treatment</measure>
    <time_frame>Up to 24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor FLT uptake (SUVmax)</measure>
    <time_frame>Baseline to 24 hours after initiation of treatment</time_frame>
    <description>Will be compared between patients from treatment arms C and D.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Stage III Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 PO daily on days 1, 2, 8, 9, 15, and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily on days 1, 2, 8, 9, 15, and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 (recommended phase II dose) as in Arm A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adavosertib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <other_name>AZD-1775</other_name>
    <other_name>AZD1775</other_name>
    <other_name>MK-1775</other_name>
    <other_name>MK1775</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>FF 10832</other_name>
    <other_name>FF-10832</other_name>
    <other_name>FF10832</other_name>
    <other_name>Gemcitabine HCI</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>Paclitaxel Albumin</other_name>
    <other_name>paclitaxel albumin-stabilized nanoparticle formulation</other_name>
    <other_name>Protein-bound Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (phase I, dose level 1)</arm_group_label>
    <arm_group_label>Arm B (phase I, dose level 2)</arm_group_label>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
    <arm_group_label>Arm D (phase II, WEE1 inhibitor MK-1775)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm C (phase II, placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PHASE I STUDY -- ARM A (DOSE LEVEL 1) AND ARM B (DOSE LEVEL 2)&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed metastatic or&#xD;
             unresectable locally advanced adenocarcinoma of the pancreas with no prior systemic&#xD;
             therapy for metastatic or locally advanced disease&#xD;
&#xD;
          -  Previous neo-adjuvant or adjuvant treatment is allowed provided that it was given &gt;= 6&#xD;
             months prior to registration&#xD;
&#xD;
          -  Patients must NOT be receiving any other investigational agents concurrently and must&#xD;
             not have received any other investigational agents =&lt; 4 weeks prior to registration&#xD;
&#xD;
          -  Patients must not have a pre-existing &gt; grade 1 motor or sensory neuropathy&#xD;
&#xD;
          -  Patients must NOT have history of allergic reactions attributed to compounds of&#xD;
             similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775&#xD;
&#xD;
          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0&#xD;
             or 1&#xD;
&#xD;
          -  Patients must have a life expectancy of &gt;= 12 weeks&#xD;
&#xD;
          -  Patients may have had prior radiotherapy for metastatic disease as long as it was &gt; 4&#xD;
             weeks prior to registration and the patient has recovered from adverse events&#xD;
             associated with the radiotherapy&#xD;
&#xD;
          -  Patients must NOT be taking current medications or substances that are inhibitors or&#xD;
             inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4)&#xD;
&#xD;
          -  Patients must NOT have uncontrolled serious medical illness including, but not limited&#xD;
             to, ongoing or active infection, cardiac arrhythmia, or psychiatric illness that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) are not eligible if cluster of&#xD;
             differentiation (CD)4 count is =&lt; 200 cell/mm^3 or if receiving antiretroviral therapy&#xD;
&#xD;
          -  Patients must be able to swallow capsules whole&#xD;
&#xD;
          -  Patients must NOT have previous or concurrent malignancy; exceptions are made for&#xD;
             patients who meet any of the following conditions:&#xD;
&#xD;
               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or&#xD;
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in situ)&#xD;
&#xD;
               -  Prior malignancy completely excised or removed and patient has been continuously&#xD;
                  disease free for &gt; 5 years&#xD;
&#xD;
          -  Patients must be able to tolerate computed tomography (CT), magnetic resonance imaging&#xD;
             (MRI) or PET imaging including contrast agents&#xD;
&#xD;
          -  Women must not be pregnant or breast-feeding&#xD;
&#xD;
               -  Females of childbearing potential must have a blood test or urine study within 5&#xD;
                  days prior to registration to rule out pregnancy; a female of childbearing&#xD;
                  potential is any woman, regardless of sexual orientation or whether they have&#xD;
                  undergone tubal ligation, who meets the following criteria: 1) has not undergone&#xD;
                  a hysterectomy or bilateral oophorectomy; or 2) has not been naturally&#xD;
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any&#xD;
                  time in the preceding 24 consecutive months)&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal and barrier method of birth control; two barrier methods of birth control;&#xD;
             abstinence) for the duration of study treatment and for 3 months after the last dose&#xD;
             of study treatment; should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately;&#xD;
             should a man impregnate or suspect that he has impregnated a woman while participating&#xD;
             in this study, he should inform his treating physician immediately&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 3 X institutional upper limit of normal (ULN) or =&lt; 5 X ULN if the patient has&#xD;
             liver metastases&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL or creatinine clearance (Cockcroft-Gault) &gt;= 60 mL/min for&#xD;
             patients with creatinine levels above institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  RANDOMIZED PHASE II STUDY -- ARMS C AND D&#xD;
&#xD;
          -  PHASE II: Patients must have histologically or cytologically confirmed metastatic&#xD;
             adenocarcinoma of the pancreas with no prior systemic therapy for metastatic disease&#xD;
&#xD;
          -  PHASE II: Patients must NOT have locally advanced disease&#xD;
&#xD;
          -  PHASE II: Patients must have measurable disease outside of the primary tumor&#xD;
             (pancreas) by RECIST 1.1 criteria; baseline measurements and evaluations of all sites&#xD;
             of disease must be obtained =&lt; 4 weeks prior to randomization&#xD;
&#xD;
          -  PHASE II: Previous neo-adjuvant or adjuvant treatment is allowed provided that there&#xD;
             was no evidence of recurrent disease for at least 6 months after completion of&#xD;
             neo-adjuvant/adjuvant treatment&#xD;
&#xD;
          -  PHASE II: Patients may have had prior radiotherapy for metastatic disease as long as&#xD;
             it was &gt; 4 weeks prior to randomization and the patient has recovered from adverse&#xD;
             events associated with the radiotherapy&#xD;
&#xD;
          -  PHASE II: Patients must NOT be taking current medications or substances that are&#xD;
             inhibitors or inducers of CYP3A4&#xD;
&#xD;
          -  PHASE II: Patients must NOT have received prior Wee1 inhibitors or AZD1775&#xD;
&#xD;
          -  PHASE II: Patients must NOT have received gemcitabine or nab-paclitaxel in a&#xD;
             metastatic setting&#xD;
&#xD;
          -  PHASE II: Patients must NOT be receiving any other investigational agents concurrently&#xD;
             and must not have received any other investigational agents =&lt; 4 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  PHASE II: Patients must not have a pre-existing &gt; grade 1 motor or sensory neuropathy&#xD;
&#xD;
          -  PHASE II: Patients must NOT have history of allergic reactions attributed to compounds&#xD;
             of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775&#xD;
&#xD;
          -  PHASE II: Patients must have ECOG performance status of 0 or 1&#xD;
&#xD;
          -  PHASE II: Patients must have a life expectancy of &gt;= 12 weeks&#xD;
&#xD;
          -  PHASE II: Patients must NOT have uncontrolled serious medical illness including, but&#xD;
             not limited to, ongoing or active infection, cardiac arrhythmia, or psychiatric&#xD;
             illness that would limit compliance with study requirements&#xD;
&#xD;
          -  PHASE II: Patients must be able to swallow capsules whole&#xD;
&#xD;
          -  PHASE II: Patients with biliary stents are allowed&#xD;
&#xD;
          -  PHASE II: Patients must NOT have previous or concurrent malignancy; exceptions are&#xD;
             made for patients who meet any of the following conditions:&#xD;
&#xD;
               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or&#xD;
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in situ)&#xD;
                  â€¢ Prior malignancy completely excised or removed and patient has been&#xD;
                  continuously disease free for &gt; 5 years&#xD;
&#xD;
          -  PHASE II: Patients must be able to tolerate CT, MRI or PET imaging including contrast&#xD;
             agents&#xD;
&#xD;
          -  PHASE II: Women must not be pregnant or breast-feeding&#xD;
&#xD;
               -  Females of childbearing potential must have a blood test or urine study within 5&#xD;
                  days prior to randomization to rule out pregnancy; a female of childbearing&#xD;
                  potential is any woman, regardless of sexual orientation or whether they have&#xD;
                  undergone tubal ligation, who meets the following criteria: 1) has not undergone&#xD;
                  a hysterectomy or bilateral oophorectomy; or 2) has not been naturally&#xD;
                  postmenopausal for at least 24 consecutive months (i.e., has had menses at any&#xD;
                  time in the preceding 24 consecutive months)&#xD;
&#xD;
          -  PHASE II: Women of child-bearing potential and men must agree to use adequate&#xD;
             contraception (hormonal and barrier method of birth control; two barrier methods of&#xD;
             birth control; abstinence) for the duration of study treatment and for 3 months after&#xD;
             the last dose of study treatment; should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately; should a man impregnate or suspect that he has impregnated a woman while&#xD;
             participating in this study, he should inform his treating physician immediately&#xD;
&#xD;
          -  PHASE II: Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  PHASE II: Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  PHASE II: Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  PHASE II: Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  PHASE II: Total bilirubin =&lt; 1.5 institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  PHASE II: AST (SGOT)/ALT (SGPT) =&lt; 3 X institutional upper limit of normal (ULN) or =&lt;&#xD;
             5 X ULN if the patient has liver metastases&#xD;
&#xD;
          -  PHASE II: Creatinine =&lt; 1.5 mg/dL or creatinine clearance (Cockcroft-Gault) &gt;= 60&#xD;
             mL/min for patients with creatinine levels above institutional upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  PHASE II: For participation in the imaging research studies, patients must meet the&#xD;
             additional following criteria:&#xD;
&#xD;
          -  PHASE II: The patient is participating in the trial at an institutional which has&#xD;
             agreed to perform the imaging research studies, completed the American College of&#xD;
             Radiation Imaging Network (ACRIN) defined scanner qualification procedures and&#xD;
             received ACRIN approval&#xD;
&#xD;
          -  PHASE II: The patient has consented in writing to participate in one of the imaging&#xD;
             research studies&#xD;
&#xD;
          -  PHASE II: The patient meets the criteria required for the imaging study in which the&#xD;
             site is participating:&#xD;
&#xD;
               -  NOTE: Eligibility for participating in either imaging sub-study will depend on&#xD;
                  the availability of the imaging sub-study at a particular institution&#xD;
&#xD;
               -  For participation in the FDG-PET sub-study:&#xD;
&#xD;
                    -  Patients must NOT have poorly controlled diabetes (defined as fasting&#xD;
                       glucose level &gt;= 200 mg/dL) despite efforts to improve glucose control by&#xD;
                       fasting duration and adjustment of medications&#xD;
&#xD;
                    -  Patient must NOT weigh more than the maximum weight limit for the PET table&#xD;
&#xD;
                    -  Patients must have an evaluable lesion of &gt; 20 mm in size on standard&#xD;
                       practice imaging study as assessed by site (either primary pancreas mass or&#xD;
                       metastasis)&#xD;
&#xD;
               -  For participation in the FLT-PET sub-study:&#xD;
&#xD;
                    -  Patients must be able to lie still for a 1.5 hour PET scan.&#xD;
&#xD;
                    -  Patient must NOT have a history of allergic reaction attributable to&#xD;
                       compounds of similar chemical or biologic composition to 18F-fluorothymidine&#xD;
&#xD;
                    -  Patient must NOT weigh more than the maximum weight limit for the PET table&#xD;
&#xD;
                    -  Patients must have an evaluable lesion in the pancreas &gt; 20 mm in size on&#xD;
                       standard practice imaging study as assessed by site (lesion must be likely&#xD;
                       primary adenocarcinoma of the pancreas that is not primarily fibrotic or&#xD;
                       mucinous in nature)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer R Eads</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOG-ACRIN Cancer Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 16, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Adavosertib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

